Home › Alnylam Receives Orphan Drug Designation From U.S. Food & Drug Administration For ALN-AT3, An RNAi Therapeutic For The Treatment Of Hemophilia
 

Keywords :   


Alnylam Receives Orphan Drug Designation From U.S. Food & Drug Administration For ALN-AT3, An RNAi Therapeutic For The Treatment Of Hemophilia

2013-09-04 06:05:53| drugdiscoveryonline News Articles

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced recently that the U.S. Food & Drug Administration (FDA) has granted an Orphan Drug Designation to ALN-AT3 as a therapeutic for the treatment of hemophilia B

Tags: the of food treatment

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05Water investors have withdrawn billions, says research
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
19.05IT Cosmetics and Kenvue Launch New Products
19.05Virgin Trains targets West Coast in return to rail
19.05Cashing In On The Stache
More »